Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30372051 | 1.00 | MAPK1 (0.61) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL846330 | 0.84 | MAPK1 (0.59) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL846331 | 0.84 | MAPK1 (0.59) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL846377 | 0.84 | MAPK1 (0.59) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL31601570 | 0.84 | MAPK1 (0.59) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL9000473 | 0.81 | MAPK1 (0.56) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL7926743 | 0.81 | CA12 (0.50) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL7389658 | 0.81 | KDM4E (0.57) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL9836119 | 0.81 | CA12 (0.41) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL20419488 | 0.81 | KDM4E (0.64) | MAPK1KDM4EL3MBTL1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113461608-B | Synthetic method of 6-formyl methyl nicotinate | 江苏弘和药物研发有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-113461608-A | Synthetic method of 6-formyl methyl nicotinate | 江苏弘和药物研发有限公司 | 2021-10-01 | — | — | CN | claimed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | claimed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| CN-115873020-B | RAS inhibitors | 锐新医药公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| CN-119977956-A | 3, 5-Disubstituted-1, 2, 4-triazole compound and preparation method and application thereof | 华东师范大学 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025095751-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | 현대약품 주식회사 | 2025-05-08 | — | — | WO | disclosed |
| CN-119677716-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-03-21 | — | — | CN | disclosed |
| US-5223522-A | Anticholesterol agents | PFIZER INC. (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0532754-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVE OR ITS SALT | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-03-24 | — | — | EP | disclosed |
| CN-1062263-A | The weed killer herbicide that contains the pyridinsulfonamide compounds of replacement | ISHIHARA SANGYO KAISHA (JP) | 1992-07-01 | — | — | CN | disclosed |
| US-5120754-A | Anticholesterol and antidiabetic agents | PFIZER INC. (US) | 1992-06-09 | — | — | US | disclosed |
| CN-1016661-B | Herbicidal composition containing pyridine sulfonamide | ISHIHARA SANGYO KAISHA (JP) | 1992-05-20 | — | — | CN | disclosed |
| US-5061717-A | ANTICHOLESTEROL AGENTS | PFIZER INC. (US) | 1991-10-29 | — | — | US | disclosed |
| WO-1989008650-A1 | THIAZOLIDINEDIONE HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1989-09-21 | — | — | WO | disclosed |
| EP-0332331-A2 | Thiazolidinedione hypoglycemic agents | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | MAPK1 202/4885KDM4E 2352/4885L3MBTL1 819/4885 |
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | MAPK1 1379/4885KDM4E 583/4885L3MBTL1 1776/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | MAPK1 4017/4885KDM4E 3220/4885L3MBTL1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.